• to decreased the potential risk of critical cardiovascular (heart and blood vessel) problems in Older people with type 2 diabetes and cardiovascular disease In October 2024, Novo Nordisk released a study on scientific journal Mother nature about a novel glucose-sensitive insulin NNC221